Price Movement and Market Comparison
On 28 Nov 2025, Shree Ganesh Biotech India recorded a closing price of ₹0.62, the lowest in its trading history. Despite a day-on-day gain of 1.61%, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained weakness in price momentum.
When compared with the Sensex, which showed a modest increase of 0.12% on the same day, the stock’s short-term outperformance is overshadowed by its longer-term trends. Over the past week, the stock declined by 3.08%, while the Sensex advanced by 0.69%. The one-month and three-month performances show declines of 16.00% and 19.23% respectively, against Sensex gains of 1.41% and 7.17%.
More strikingly, the stock’s year-to-date performance stands at -39.42%, contrasting with the Sensex’s 9.83% rise. Over one year, the stock has fallen by 41.12%, while the Sensex appreciated by 8.58%. The three-year and five-year figures reveal even more pronounced disparities, with Shree Ganesh Biotech India down 63.16% and 87.16% respectively, compared to Sensex gains of 37.31% and 94.39%. The ten-year performance shows no change for the stock, whereas the Sensex has surged by 228.47%.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Financial Performance and Profitability Metrics
Shree Ganesh Biotech India’s financial results for the nine months ending September 2025 indicate a contraction in net sales to ₹5.16 crores, reflecting a decline of 44.64% compared to the previous period. Correspondingly, the company reported a net loss after tax of ₹0.61 crores, also reflecting a 44.64% change in the same period.
The company’s ability to convert sales into profits remains limited, with an average return on equity of 2.62%, signalling modest profitability relative to shareholders’ funds. Additionally, the average EBIT to interest ratio stands at 0.91, suggesting challenges in covering interest expenses from operating earnings.
Debtors turnover ratio for the half-year period is recorded at 0.00 times, indicating potential issues in realising receivables efficiently. The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) have been negative, underscoring the financial strain faced by the business.
Valuation and Risk Considerations
From a valuation perspective, Shree Ganesh Biotech India is trading at levels considered risky relative to its historical averages. The stock’s return over the past year of -41.12% coincides with a profit decline of 86.6%, highlighting the extent of financial pressure. The market capitalisation grade is noted as 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector.
Majority shareholding is held by non-institutional investors, which may influence liquidity and trading dynamics. The stock’s performance relative to its sector peers has been subdued, with the sector showing positive trends while the company’s stock price continues to face downward pressure.
Considering Shree Ganesh Biotech India ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Biotech India’s stock performance diverges markedly from sectoral trends. While the broader sector has demonstrated resilience and growth, this company’s stock has experienced sustained declines over multiple time horizons. This divergence is evident in the stock’s relative underperformance against the Sensex and sector benchmarks.
The company’s market capitalisation and trading volumes reflect its micro-cap status, which may contribute to heightened volatility and sensitivity to market developments. The stock’s current price level at ₹0.62 represents a critical point in its valuation history, underscoring the challenges faced in regaining investor confidence.
Summary of Key Metrics
To summarise, Shree Ganesh Biotech India’s key financial and market metrics as of 28 Nov 2025 are as follows:
- All-time low stock price: ₹0.62
- One-day price change: +1.61%
- One-year stock return: -41.12%
- Net sales (9 months): ₹5.16 crores, down 44.64%
- Net loss after tax (9 months): ₹0.61 crores
- Return on equity (average): 2.62%
- EBIT to interest ratio (average): 0.91
- Debtors turnover ratio (half-year): 0.00 times
- Negative EBITDA reported
These figures collectively illustrate the extent of the company’s current financial and market position.
Conclusion
Shree Ganesh Biotech India’s stock reaching an all-time low price of ₹0.62 marks a significant event in its trading history. The company’s financial data reveals a pattern of declining sales and profitability, accompanied by valuation levels that reflect elevated risk. The stock’s performance contrasts sharply with broader market indices and sectoral trends, highlighting the challenges faced by the company in its current phase.
Investors and market participants observing this stock will note the persistent downward trend across multiple time frames and the financial metrics that underpin this movement. The stock’s position below all major moving averages further emphasises the prevailing market sentiment.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
